Table 1.
General characteristics and outcomes of the patients
| Characteristics | Results |
|---|---|
| Number of the patients | 63 |
| Age (years) | 50.4 ± 19.0 |
| Sex (male, %) | 47.6 |
| APACHE II | 15.0 ± 5.1 |
| Mechanical ventilation (%) | 68.8 |
| Infections (%) | |
| Lung | 18.8 |
| Blood | 12.5 |
| Abdominal cavity | 43.8 |
| Urinary system | 9.4 |
| Others | 15.6 |
| Baseline cardiac function (%) | |
| NYHA I | 54.0 |
| NYHA II | 36.5 |
| NYHA III | 9.5 |
| NE dose (µg·kg−1·min−1) | 0.47 ± 0.17 |
| Maximum dose of esmolol (mg/h) | 113.6 ± 89.7 |
| Total dose of esmolol (mg) | 187.8 ± 110.7 |
| Time to achieve target heart rate (h) | 1.7 ± 0.3 |
| Outcomes | |
| Hospital stay (days) | 22.7 ± 17.0 |
| ICU stay (days) | 12.0 ± 16.5 |
| 28-day mortality rate (%) | 6.3 |
| In-hospital mortality rate (%) | 7.8 |
ICU: Intensive Care Unit; APACHE: Acute Physiology and Chronic Health Evaluation; NYHA: New York Heart Association; NE: Norepinephrine.